T Cell Lymphomas
Conference Coverage
Study halted; ‘hyperprogression’ seen with nivolumab for R/R PTCL
ORLANDO –
Conference Coverage
HDAC/HMA combo shows ‘remarkable’ activity in PTCL
LUGANO, SWITZERLAND – Patients with AITL and PTCL-TFH subtypes had high overall response rates to romidepsin and AZA.
News
Lymphoma risk prompts FDA recall of Allergan’s textured breast implants
The FDA asked Allergan to recall six brands of textured breast implants and expanders because of the lymphoma risk they pose.
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
From the Journals
Case report may link gluteal implants to lymphoma
On the heels of increased reports of breast implant–related anaplastic large cell lymphoma, researchers report a case of lymphoma that may be...
From the Journals
Alisertib response rate in PTCL patients was 33%
New report explains alisertib’s performance in terminated phase 3 trial.
From the Journals
Hidradenitis suppurativa linked to increased lymphoma risk
The risks of Hodgkin, non-Hodgkin, and cutaneous T-cell lymphoma were more common among males than females.
Conference Coverage
Increased risk of second cancers in mycosis fungoides
LA JOLLA, CALIF. – Researchers found the risk of second malignancy was highest among MF patients aged 30 to 50 years and patients who had tumor...
News
FDA: 246 new reports on breast implant-associated lymphoma
The latest update from the Food and Drug Administration includes medical device reports between September 2017 and September 2018.
Conference Coverage
Cobomarsen shows early promise for treating ATLL
LA JOLLA, CALIF. – A small number of patients experienced disease stabilization or regression on cobomarsen.
Conference Coverage
Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
LA JOLLA, CALIF. – Some CTCL patients experienced relief from itching after just one pill.